Leading the way to early diagnosis.

The damage to joints caused by RA is irreversible. We are focused on identifying biomarkers to diagnose RA at the onset of the disease to avoid joint erosions and other damage. QUANTA Flash® and QUANTA Lite® CCP3 assays aid in the early diagnosis of this disease, where prompt initiation of treatment can greatly benefit patients.

  • Giving patients earlier answers.
    We help improve patient care by providing tests that can aid in the early diagnosis of RA for prompt treatment.
  • Accurate lab results.
    Labs feel good knowing that our RA assays aid in early disease detection while delivering highly accurate results.
  • Bringing clinicians more options.
    Clinicians appreciate our research into new biomarkers that may provide additional insight into diagnosis, prognosis and disease activity monitoring for RA.